Charmacy Pharmaceutical Co Ltd

Charmacy's capital structure is characterized by a debt-to-equity ratio of 1.94, indicating a relatively high reliance on debt financing. The company holds 753.6 million CNY in cash and equivalents, but this is offset by 1.195 billion CNY in long-term debt, resulting in a net cash position that is negative. The current ratio of 1.09 suggests limited short-term liquidity, with current assets barely covering current liabilities. Profitability metrics show a return on equity (ROE) of 7.51% and a return on assets (ROA) of 1.17%, both below the typical thresholds for high-performing pharmaceutical distributors. The gross profit margin is 7.53%, and the operating margin is 1.55%, which are in line with the industry's median for gross margin but below the median for operating margin. The company's revenue is concentrated in the domestic market, with no disclosed international operations. It operates through a single business segment focused on pharmaceutical distribution, with no material diversification into other product lines or geographic regions. Looking ahead, Charmacy's revenue is projected to grow by 7.3% in the current fiscal year and 5.1% in the next, based on analyst estimates. This growth is modest compared to the industry's average, and the company's net income is expected to remain flat or decline slightly due to margin compression from competitive pricing pressures. The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after subtracting total debt. While dilution risk is currently low, the company has a history of issuing shares, and any future capital raising could increase dilution potential. The valuation is supported by a price-to-earnings ratio of 13.58 and a price-to-book ratio of 1.02, which are in line with the industry median. Recent filings and transcripts indicate that Charmacy is focusing on expanding its logistics and consulting services to diversify revenue streams. The company has also been investing in digital transformation to improve supply chain efficiency. However, there are no material new product launches or strategic acquisitions disclosed in the latest reports.